{"id":"NCT01623323","sponsor":"Optinose US Inc.","briefTitle":"Study Evaluating the Safety of Intranasal Administration of 400 μg of Fluticasone Propionate Twice a Day (BID) Using a Novel Bi-Directional Device in Subjects With Chronic Sinusitis With or Without Nasal Polyps","officialTitle":"A 3-Month Open-Label Multicenter Study Evaluating the Safety of Intranasal Administration of 400 μg of Fluticasone Propionate Twice a Day (BID) Using a Novel Bi-Directional Device in Subjects With Chronic Sinusitis With or Without Nasal Polyps","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2013-09","primaryCompletion":"2015-03","completion":"2015-03","firstPosted":"2012-06-19","resultsPosted":"2016-03-01","lastUpdate":"2016-08-29"},"enrollment":705,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Chronic Sinusitis With or Without Nasal Polyps"],"interventions":[{"type":"DRUG","name":"Fluticasone Propionate","otherNames":[]}],"arms":[{"label":"Fluticasone","type":"OTHER"}],"summary":"This is an open-label, multicenter study designed to assess the safety of intranasal administration of 400 μg of fluticasone propionate twice a day delivered by the OptiNose device in subjects with chronic sinusitis with or without nasal polyps. The study consists of an up-to-7-day pretreatment phase followed a 3-month open-label treatment phase. The duration of each subject's participation is approximately 13 weeks.","primaryOutcome":{"measure":"Adverse Events","timeFrame":"Baseline to 3 months or End of Study","effectByArm":[{"arm":"OPN-375","deltaMin":270,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":26},"locations":{"siteCount":18,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":5,"n":705},"commonTop":["epistaxis","Nasal Mucosal Disorder","Nasal Septal Disorder"]}}